Acalabrutinib – July 2026

  • Brand names:
    • Calquence®
  • Pharmaceutical Company:
    • ASTRAZENECA PTY LTD
  • Condition/Indication: Mantle cell lymphoma (MCL)
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026